A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Burning Rock Biotech Ltd
BNR
$11.62
-3.09%
Business description not available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 540M | 540M | 516M | 537M | 563M | 508M |
| Net Income | -7.9M | -7.9M | -47M | -92M | -141M | -125M |
| EPS | $0.00 | - | - | - | - | $0.00 |
| Free Cash Flow | -4.8M | -4.8M | -13M | -37M | -75M | -107M |
| ROIC | -43.4% | -10.1% | -50.6% | -66.7% | -61.6% | -37.9% |
| Gross Margin | 10.7% | 10.7% | 9.6% | 9.5% | 9.8% | 11.3% |
| Debt/Equity | 0.08 | 0.08 | 0.09 | 0.02 | 0.04 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -7.8M | -7.8M | -49M | -94M | -142M | -125M |
| Operating Margin | -1.5% | -1.5% | -9.5% | -17.5% | -25.2% | -24.6% |
| ROE | -10.3% | -10.1% | -50.6% | -66.7% | -61.6% | -37.9% |
| Shares Outstanding | 0M | - | - | - | - | - |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 209M | 382M | 430M | 508M | 563M | 537M | 516M | 540M | 540M |
| Gross Margin | 64.7% | 71.6% | 11.2% | 11.3% | 9.8% | 9.5% | 9.6% | 10.7% | 10.7% |
| R&D | 105M | 157M | 40M | 58M | 61M | 49M | 32M | 24M | 24M |
| SG&A | 88M | 132M | 45M | 77M | 82M | 62M | 36M | 18M | 18M |
| EBIT | -161M | -169M | -63M | -125M | -142M | -94M | -49M | -7.8M | -7.8M |
| Op. Margin | -77.3% | -44.3% | -14.7% | -24.6% | -25.2% | -17.5% | -9.5% | -1.5% | -1.5% |
| Net Income | -232M | -334M | -72M | -125M | -141M | -92M | -47M | -7.9M | -7.9M |
| Net Margin | -111.2% | -87.6% | -16.8% | -24.6% | -25.0% | -17.1% | -9.2% | -1.5% | -1.5% |
| Non-Recurring | -37K | -184K | -34K | -28K | -206K | -142K | -301K | 29K | 29K |
| Returns on Capital | |||||||||
| ROIC | N/A | -20.0% | -15.5% | -37.9% | -61.6% | -66.7% | -50.6% | -10.1% | -43.4% |
| ROE | 47.6% | 44.7% | 27.8% | -37.9% | -61.6% | -66.7% | -50.6% | -10.1% | -10.3% |
| ROA | N/A | -78.8% | -11.5% | -32.7% | -47.9% | -48.9% | -35.5% | -6.6% | -6.7% |
| Cash Flow | |||||||||
| Op. Cash Flow | -149M | -228M | -11M | -75M | -66M | -36M | -13M | -4.1M | -4.1M |
| Free Cash Flow | -172M | -271M | -21M | -107M | -75M | -37M | -13M | -4.8M | -4.8M |
| Owner Earnings | -179M | -282M | -43M | -127M | -132M | -92M | -41M | -9.2M | -9.2M |
| CapEx | 23M | 43M | 9.2M | 32M | 9.0M | 1.1M | 742K | 751K | 751K |
| Maint. CapEx | 25M | 31M | 5.1M | 7.5M | 18M | 19M | 7.2M | 3.1M | 3.1M |
| Growth CapEx | 0 | 12M | 4.1M | 25M | 0 | 0 | 0 | 0 | 0 |
| D&A | 25M | 31M | 5.1M | 7.5M | 18M | 19M | 7.2M | 3.1M | 3.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 3.6M | 0 | 0 | 2.4M | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 5.1M | 23M | 27M | 44M | 47M | 37M | 21M | 2.0M | 2.0M |
| Debt Repayment | 3.0M | 87M | 39M | 5.4M | 0 | 0 | 0 | 14K | 14K |
| Balance Sheet | |||||||||
| Net Debt | 3.3M | -388M | -340M | -221M | -124M | -85M | -64M | -62M | -62M |
| Cash & Equiv. | 93M | 94M | 290M | 225M | 131M | 87M | 71M | 68M | 68M |
| Long-Term Debt | 97M | 18M | 0 | 0 | 0 | 0 | 0 | 243K | 243K |
| Debt/Equity | -0.16 | -0.02 | 0.02 | 0.05 | 0.04 | 0.02 | 0.09 | 0.08 | 0.08 |
| Interest Coverage | -9.0 | -18.8 | -619.7 | -519.0 | -9476.3 | -3041.0 | -457.8 | -78.4 | -78.4 |
| Equity | -603M | -891M | 371M | 290M | 168M | 108M | 80M | 77M | 77M |
| Total Assets | N/A | 848M | 408M | 358M | 230M | 146M | 121M | 117M | 117M |
| Total Liabilities | N/A | 212M | 37M | 68M | 62M | 38M | 42M | 41M | 41M |
| Intangibles | N/A | 343K | 530K | 808K | 288K | 136K | 58K | 41K | 41K |
| Retained Earnings | N/A | -946M | -217M | -350M | -464M | -543M | -575M | -609M | -609M |
| Working Capital | N/A | 542M | 350M | 227M | 123M | 87M | 70M | 70M | 70M |
| Current Assets | 3.1M | 707M | 387M | 286M | 183M | 125M | 106M | 106M | 106M |
| Current Liabilities | N/A | 164M | 37M | 58M | 60M | 37M | 36M | 35M | 35M |
| Per Share Data | |||||||||
| EPS | -10.38 | -14.23 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | 0.00 |
| Owner EPS | -7.98 | -12.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Book Value | -26.96 | -37.96 | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Cash Flow/Share | -6.65 | -9.71 | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 22.4M | 23.5M | N/A | N/A | N/A | N/A | N/A | N/A | 0.0M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.62 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.62 |
Burning Rock Biotech Ltd passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 10.2%.
Burning Rock Biotech Ltd (BNR) has a 5-year average return on invested capital (ROIC) of -45.4%. This is below average and may indicate limited pricing power.
Burning Rock Biotech Ltd (BNR) does not currently pay a regular dividend.
Burning Rock Biotech Ltd (BNR) reported annual revenue of $540 million in its most recent fiscal year, based on SEC EDGAR filings.
Burning Rock Biotech Ltd (BNR) has a net profit margin of -1.5%. The company is currently unprofitable.
Burning Rock Biotech Ltd (BNR) generated $-5 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Burning Rock Biotech Ltd (BNR) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
Burning Rock Biotech Ltd (BNR) has a return on equity (ROE) of -10.1%. A negative ROE may indicate losses or negative equity.
Burning Rock Biotech Ltd (BNR) has a 5-year average gross margin of 10.2%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 8 years of financial data for Burning Rock Biotech Ltd (BNR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent press releases.